What is the optimal latent tuberculosis infection treatment regimen for a healthcare worker who has a positive QuantiFERON‑Gold test, a normal chest X‑ray, and was exposed to a patient with pulmonary tuberculosis that is isoniazid‑resistant based on drug susceptibility testing?

Treatment Recommendation for INH-Resistant LTBI in Healthcare Worker

For a healthcare worker with positive QuantiFERON-Gold, normal chest X-ray, and documented exposure to isoniazid-resistant pulmonary TB, treat with 4 months of daily rifampin (rifampicin) monotherapy.

Rationale and Evidence Base

The 2020 CDC/NTCA guidelines explicitly address this scenario and designate 4 months of daily rifampin as a preferred regimen with strong evidence (moderate quality) for HIV-negative individuals 1. This is the most appropriate choice when isoniazid cannot be used due to source case resistance.

Why Rifampin Monotherapy is Optimal Here:

• Efficacy: Network meta-analysis shows 3-4 months rifampin reduces TB disease risk significantly (OR 0.25,95% CI: 0.11-0.57) compared to no treatment 1
• Completion rates: Substantially higher than isoniazid regimens (80% vs 58% for 9-month INH in healthcare workers) 2
• Safety profile: Lower hepatotoxicity rates than isoniazid-containing regimens 1, 3
• Shorter duration: 4 months vs 6-9 months for alternative regimens improves adherence in working professionals

Alternative Considerations (If Rifampin Contraindicated):

If rifampin cannot be used due to drug interactions (warfarin, oral contraceptives, antiretrovirals), consider:

1. Rifabutin (fewer drug interactions than rifampin) for similar duration 1
2. Fluoroquinolone-based regimen (moxifloxacin or levofloxacin) - though this is extrapolated from active INH-resistant TB treatment data showing improved outcomes (aOR 2.8,95% CI: 1.1-7.3) 4

Critical Implementation Points

Do NOT use:

• Any isoniazid-containing regimen (3HP, 3HR, 6H, 9H) - the source organism is INH-resistant by DST 4, 5
• The standard 3-month isoniazid-rifapentine weekly regimen is contraindicated here

Before initiating treatment:

• Confirm active TB is excluded (you've done this with negative chest X-ray)
• Check baseline liver function tests
• Screen for rifampin drug interactions (particularly oral contraceptives, which will require alternative contraception)
• Consider baseline CBC given rare rifampin-associated thrombocytopenia 3

Monitoring during treatment:

• Monthly clinical assessment for adherence and adverse effects
• Liver function testing if symptoms develop (hepatotoxicity risk ~3-4% with rifampin alone) 3
• Consider directly observed therapy if adherence concerns exist 1

Common Pitfalls to Avoid

1. Don't default to standard LTBI regimens: The INH resistance changes everything - using 3HP or 9H would be ineffective and potentially select for additional resistance
2. Don't delay treatment: Healthcare workers remain at ongoing occupational risk
3. Don't forget drug interactions: Rifampin is a potent CYP450 inducer affecting numerous medications 1
4. Don't assume completion: Even with shorter regimens, only 80% of HCWs complete therapy - emphasize importance and consider incentives 2

Dosing: Rifampin 600 mg daily (or 10 mg/kg if <50 kg) for 4 months 1

This recommendation prioritizes preventing progression to active TB (mortality/morbidity outcome) while maximizing treatment completion through a shorter, better-tolerated regimen that addresses the documented INH resistance.